Tirzepatide is a dual GIP/GLP-1 receptor agonist with established Phase 3 evidence and regulatory approvals for clinical use in multiple jurisdictions. Retatrutide (LY3437943) is an investigational triple agonist that adds glucagon-receptor activity to GIPR and GLP-1R signalling. Published Phase 2 retatrutide data and 2026 Phase 3 topline announcements have increased scientific interest, but a direct Phase 3 comparison with tirzepatide—TRIUMPH-5—has not yet reported results. That distinction matters: separate trials cannot establish which molecule is superior.
Retatrutide vs tirzepatide at a glance
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Development code | LY3437943 | LY3298176 |
| Receptor targets | GIPR + GLP-1R + GCGR | GIPR + GLP-1R |
| Common description | Triple agonist | Dual agonist |
| Glucagon-receptor activity | Yes | No |
| Clinical status, Aug 2026 | Investigational; not approved for human use | Approved prescription medicine in multiple jurisdictions |
| Direct head-to-head trial | TRIUMPH-5: Phase 3 retatrutide vs tirzepatide; active, not recruiting; results not yet posted | |
Why researchers compare retatrutide with tirzepatide
The comparison is scientifically natural because both molecules share two receptor targets—GIPR and GLP-1R—but retatrutide adds a third target, the glucagon receptor (GCGR). That makes tirzepatide a useful reference point for asking a narrower mechanistic question: what changes when glucagon-receptor agonism is added to an already established dual-incretin framework?
The answer is not simply “three receptors are stronger than two.” Multireceptor pharmacology depends on relative potency, exposure, tissue distribution, signalling bias and the physiological effects produced by each receptor. More targets can create new opportunities, but they can also introduce new trade-offs.
What is tirzepatide?
Tirzepatide is a single peptide engineered to activate both the GIP receptor and GLP-1 receptor. Its pharmacology is not a 50/50 combination: published mechanistic work describes stronger relative engagement of GIPR and biased signalling at GLP-1R, illustrating why receptor count alone is an incomplete description of a molecule.
In the Phase 3 SURMOUNT-1 obesity trial, adults without diabetes were randomized to tirzepatide or placebo for 72 weeks. Mean body-weight change under the treatment-regimen estimand was −15.0% with 5 mg, −19.5% with 10 mg and −20.9% with 15 mg, compared with −3.1% with placebo. These results established a strong clinical benchmark for dual GIP/GLP-1 agonism.
What is retatrutide?
Retatrutide is an investigational peptide designed to activate GIPR, GLP-1R and GCGR. Discovery work reported balanced GLP-1R and GCGR activity with greater GIPR activity in vitro, while preclinical experiments supported a development hypothesis in which incretin-linked reductions in energy intake are combined with glucagon-receptor-mediated effects on energy expenditure and substrate handling.
In the peer-reviewed Phase 2 obesity trial, 338 adults received retatrutide or placebo for 48 weeks. Mean body-weight change reached −24.2% in the 12 mg group versus −2.1% with placebo. The most common adverse events were gastrointestinal, and dose-dependent increases in heart rate were observed. Those data justified Phase 3 development but do not by themselves establish superiority over tirzepatide because the trials differed substantially.
Triple vs dual agonism: the receptor-level difference
Both molecules activate the glucose-dependent insulinotropic polypeptide receptor, an incretin receptor involved in nutrient-responsive insulin secretion and broader metabolic signalling.
Both activate the glucagon-like peptide-1 receptor, which participates in glucose-dependent insulin secretion, glucagon regulation, gastrointestinal signalling and central appetite pathways.
Retatrutide additionally activates the glucagon receptor, introducing effects related to hepatic substrate handling, glucose output and energy-expenditure pathways.
The addition of GCGR is the defining structural-pharmacology difference. The research objective is to determine whether glucagon-receptor activity adds clinically useful metabolic effects while maintaining an acceptable safety and glycaemic profile.
What does glucagon-receptor agonism add?
Glucagon is often discussed primarily in the context of raising blood glucose, but glucagon-receptor signalling also affects lipid mobilization, substrate oxidation and energy expenditure. Retatrutide’s design attempts to combine those effects with GIPR and GLP-1R activity that can support glucose-dependent endocrine control and reduce energy intake.
That balance is the central scientific hypothesis behind triple agonism. It is also why the molecule cannot be understood as “tirzepatide plus one extra receptor.” Relative receptor potency and downstream signalling determine whether the third target is beneficial, neutral or limiting at a given exposure.
What the clinical evidence shows—and what it does not
Both development programs have produced large changes in body weight in controlled trials, but the most frequently quoted percentages come from different studies with different durations, populations, dose-escalation schemes and statistical estimands.
| Study | Molecule | Design context | Selected reported result |
|---|---|---|---|
| SURMOUNT-1 | Tirzepatide | Phase 3; 72 weeks; adults with obesity/overweight without diabetes | −20.9% mean change at 15 mg under the treatment-regimen estimand |
| Retatrutide Phase 2 | Retatrutide | Phase 2; 48 weeks; adults with obesity/overweight | −24.2% least-squares mean change at 12 mg |
| TRIUMPH-1 | Retatrutide | Phase 3; 80 weeks; company topline release in 2026 | −28.3% average change reported at 12 mg |
Those numbers provide context, not a valid ranking. A larger percentage in one study does not prove that the molecule would outperform another when tested in the same population under the same protocol.
TRIUMPH-5: the comparison that matters most
This is important for SEO headlines and scientific interpretation alike: until a direct comparison is available, claims that retatrutide is “better,” “stronger” or “more effective” than tirzepatide remain unproven. TRIUMPH-5 is designed to answer that question much more directly than comparisons assembled from separate trials.
Where retatrutide Phase 3 research stands in 2026
Lilly reported positive topline Phase 3 results from TRIUMPH-1 in May 2026 and from TRIUMPH-2 and TRIUMPH-3 in July 2026. The company has stated that these studies form part of the clinical package intended to support future regulatory submissions. Detailed peer-reviewed publications for all of these Phase 3 datasets were not yet available at the time this article was reviewed.
That creates an important evidence distinction: peer-reviewed published data allow independent inspection of methods and results, whereas topline company announcements provide selected outcomes ahead of full publication. Both can be discussed, but they should not be treated as equivalent evidence.
How the safety evidence differs
Tirzepatide has a substantially more mature safety dataset because it has completed large clinical programs and is approved for clinical use in multiple jurisdictions. Its regulatory labels provide formal warnings, contraindications and adverse-reaction information based on evaluated clinical data.
Retatrutide remains investigational. In the Phase 2 obesity trial, gastrointestinal events were the most common adverse events and dose-dependent heart-rate increases were reported. Phase 3 topline announcements add information, but the complete safety profile will depend on full publications, larger cumulative exposure and regulatory review.
No responsible comparison should infer that one molecule is safer solely from headline adverse-event rates in separate trials.
Research-material characterization: identity is not activity
For laboratory research, the difference between a dual and triple agonist creates an analytical challenge. Chemical tests can support identity, purity and content, but they do not establish receptor-specific functional activity.
Supports molecular-mass confirmation and can help identify selected variants or degradation products.
Profiles related substances under a defined method but does not prove receptor activity.
Measures the amount of target material rather than relying on chromatographic area percentage alone.
Receptor-specific cell assays are needed to evaluate GIPR, GLP-1R and, for retatrutide, GCGR activity.
For retatrutide specifically, a claim of “triple agonist” activity requires biological evidence at all three receptors. HPLC purity or correct molecular mass alone cannot establish that pharmacology.
Frequently asked questions
What is the main difference between retatrutide and tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates those same two receptor systems and adds glucagon-receptor agonism.
Why is retatrutide called a triple agonist?
Because one molecule is designed to produce agonist activity at three receptors: GIPR, GLP-1R and GCGR.
Is retatrutide more effective than tirzepatide?
That has not been established by a completed direct comparison. Separate trials have reported large effects for both molecules, but cross-trial percentages are not proof of superiority. TRIUMPH-5 is the Phase 3 head-to-head trial designed to compare them directly.
Is there a retatrutide vs tirzepatide head-to-head trial?
Yes. TRIUMPH-5 (NCT06662383) directly compares retatrutide with tirzepatide in adults with obesity. As of August 28, 2026, it is active, not recruiting, and has no posted results.
Is retatrutide approved in Canada?
No. As of August 28, 2026, retatrutide has not been approved for human use by Health Canada. It remains investigational.
Can HPLC purity prove that retatrutide is a triple agonist?
No. HPLC can support a purity assessment under a defined method. Receptor-specific functional activity requires appropriate biological assays.
Key takeaways
Tirzepatide targets GIPR and GLP-1R; retatrutide adds GCGR.
GCGR activity changes the metabolic hypothesis and the potential trade-offs.
Different study designs mean published percentages should not be treated as a direct contest.
The ongoing Phase 3 head-to-head trial is designed to provide the most informative direct comparison.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism. 2022.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020.
- ClinicalTrials.gov. TRIUMPH-5: Retatrutide Compared to Tirzepatide in Adults Who Have Obesity. NCT06662383.
- Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results. May 21, 2026.
- Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results. July 23, 2026.
- Lilly Canada. Public Safety Notice: Unapproved and Illegal Retatrutide Products. August 13, 2026.
Primary literature and trial registries are prioritized. Company topline announcements are identified separately because full peer-reviewed datasets may not yet be available.